{"id":"NCT01018511","sponsor":"Astellas Pharma Europe B.V.","briefTitle":"Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms","officialTitle":"A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg and Tamsulosin Hydrochloride OCAS 0.4 mg Monotherapy, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01-11","primaryCompletion":"2011-03-01","completion":"2011-03-01","firstPosted":"2009-11-23","resultsPosted":"2015-12-17","lastUpdate":"2024-12-03"},"enrollment":1334,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms"],"interventions":[{"type":"DRUG","name":"Placebo tamsulosin hydrochloride OCAS 0.4 mg","otherNames":[]},{"type":"DRUG","name":"Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg","otherNames":[]},{"type":"DRUG","name":"Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg","otherNames":[]},{"type":"DRUG","name":"tamsulosin hydrochloride OCAS 0.4 mg","otherNames":["Harnal ®","Omnic®","Flomax®","YM617"]},{"type":"DRUG","name":"tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)","otherNames":["Vesomni","EC905"]},{"type":"DRUG","name":"tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)","otherNames":["EC905"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"TOCAS 0.4 mg","type":"ACTIVE_COMPARATOR"},{"label":"FDC 0.4 mg/6 mg","type":"EXPERIMENTAL"},{"label":"FDC 0.4 mg/9 mg","type":"EXPERIMENTAL"}],"summary":"Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS associated with BPH with a substantial storage component.","primaryOutcome":{"measure":"Change From Baseline to End of Treatment in Total International Prostate Symptom Score","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-5.4,"sd":0.41},{"arm":"TOCAS 0.4 mg","deltaMin":-6.2,"sd":0.42},{"arm":"FDC 0.4 mg/6 mg","deltaMin":-7,"sd":0.41},{"arm":"FDC 0.4 mg/9 mg","deltaMin":-6.5,"sd":0.42}],"pValues":[{"comp":"OG001 vs OG002","p":"0.001"},{"comp":"OG001 vs OG003","p":"0.028"},{"comp":"OG001 vs OG002","p":"0.048"},{"comp":"OG001 vs OG003","p":"0.483"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"0.006"},{"comp":"OG000 vs OG001","p":"0.039"}]},"eligibility":{"minAge":"45 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":118,"countries":["Austria","Belarus","Belgium","Czechia","France","Germany","Hungary","Italy","Netherlands","Poland","Russia","Slovakia","United Kingdom"]},"refs":{"pmids":["23932438"],"seeAlso":["https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=38"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":341},"commonTop":["Dry mouth","Constipation"]}}